Indacaterol maleate

DRUG6 trials

Sponsors

Novartis, University of Milan, Novartis Pharmaceuticals

Conditions

AsthmaCOPDDyspneaHealthyHypoxemiaLung DiseasesLung Diseases, ObstructivePulmonary Disease, Chronic Obstructive

Phase 1

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

CompletedNCT00624702

Start: 2008-02-29End: 2008-09-30Updated: 2020-12-19

Phase 2

Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00396604

NovartisCOPD, Lung Diseases, Obstructive, Pulmonary Disease, Chronic Obstructive

Start: 2006-10-31End: 2007-01-31Updated: 2011-10-25

Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

CompletedNCT00403637

Start: 2006-11-30End: 2007-02-28Updated: 2016-11-18

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

CompletedNCT03257995

Novartis PharmaceuticalsAsthma

Start: 2017-09-05End: 2018-01-18Updated: 2021-01-05

Phase 4

Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea

CompletedNCT01377051

University of MilanCOPD, Dyspnea, Hypoxemia +2

Start: 2011-05-31End: 2011-09-30Updated: 2014-10-29

Closing Volume Interpretation and Bronchodilators Effect

CompletedNCT01437748

University of MilanCOPD, Healthy

Start: 2011-08-31End: 2014-09-30Updated: 2014-10-29

Related Papers

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients

Respiratory Research2020-09-236 citations